This site is using cookies. Privacy Policy.

BioPharmaceuticals

Collaboration is in our genes 

The Netherlands has an excellent reputation in the areas of immuno-oncology, neurology, infectious diseases, aging, regenerative medicine and stem cells. With a very well-documented population, the Netherlands offers high-quality infrastructure for pharmaceutical data and analysis. The regulatory process also offers a very clear cut and trustworthy path towards regulatory decisions.

On 20 November 2017, the General Affairs Council of the European Union decided that the European Medicines Agency (EMA) will relocate to Amsterdam when it leaves London in 2019. The Netherlands Medicines Evaluation Board (MEB) is a major contributor of expertise to the European network of pharmaceutical authorities coordinated by EMA. Amsterdam becoming the new home for EMA in Spring 2019, will strengthen the Dutch ecosystem for all human and veterinary medicines. It will also boost the Netherlands’ attractiveness to other companies and institutions in life sciences and health.

Major multinationals and innovative biotech companies like Janssen, Merck (MSD), Amgen, Sanofi, Genmab, Synthon, AstraZeneca, Kite Pharma, Aduro Biotech, Galapagos, AbbVie, Kiadis, Pharming, Merus and PRA Health Sciences, as well as state-of-the-art research institutes, make the Netherlands one of the most innovative countries in the world for BioPharmaceuticals.

The Netherlands: the Most Innovative Biopharmaceutical Community in Europe

A powerful team, ready to help

The Invest in Holland network is a collaborative team of the Netherlands Foreign Investment Agency (NFIA), regional economic development agencies and several large cities. The network works to provide a continuum of free, confidential support services to new foreign investors, as well as existing foreign investors that already have operations in the Netherlands.

World-Class Research & Education

pharmaceutical

"Amsterdam ticks many of our boxes. It offers excellent connectivity and a building that can be shaped according to our needs. I am very grateful that the [European] Member States took into account our requirements for business continuity and gave priority to the protection of public and animal health." Professor Guido Rasi Executive Director
European Medicines Agency (EMA)
5 Jul 2019

Fujifilm Irvine Scientific Locates Biopharmaceutical Manufacturing Facility in the Netherlands

4 Jun 2019

Rakuten Medical Opens European Headquarters in the Netherlands

31 Oct 2018

Alnylam Pharmaceuticals Expands Operations in the Netherlands

The Orange Blog

View Recent Posts

Get In Touch

Contact Us